XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Shareholders' Equity
3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Shareholders' Equity . Stockholders’ Equity

Public Offering of Common Stock

On March 15, 2021, the Company sold (i) an aggregate of 57,479,978 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) for $1.45 per share, of which 11,694,150 shares were issued pursuant to the underwriters’ option to purchase additional shares, and (ii) pre-funded warrants to purchase an aggregate of 32,175,172 shares of Common Stock at an exercise price of $0.001 per share (the “2021 Pre-Funded Warrants”) for $1.449 per warrant (collectively, the “Public Offering”).

The Company determined that the securities issued in the Public Offering were free-standing and that the 2021 Pre-Funded Warrants did not contain any settlement obligations that would result in liability classification under ASC 480, Distinguishing Liability from Equity and ASC 815-40, Contracts in Entity’s Own Equity. The shares encompassed in the 2021 Pre-Funded Warrants were sold at the same price as the underlying common stock, less $0.001 (which represents the exercise price of the warrants).

The Public Offering resulted in net proceeds to the Company of approximately $122.2 million, after deducting final underwriting discounts, commissions and offering expenses, as follows (in thousands):

Financial instruments

 

Proceeds

 

Common stock

 

$

83,346

 

2021 Pre-funded Warrants

 

 

46,622

 

Total

 

 

129,968

 

Offering expenses

 

 

(7,737

)

Net proceeds

 

$

122,231

 

The Company intends to use the net proceeds from the Public Offering to fund the clinical development of molgramostim for the treatment of aPAP and other general corporate purposes.

Milestone Warrants

Immediately prior to the Public Offering, the Company entered into separate, privately-negotiated warrant repurchase agreements with certain holders of its outstanding milestone warrants, each dated as of December 24, 2019. The Company paid $3.9 million ($0.15 per share of Common Stock underlying each milestone warrant) to repurchase milestone warrants with 26,061,769 shares of Common Stock underlying such warrants, and the warrants were terminated. The warrant repurchase was accounted for as an equity transaction and resulted in a reduction to Additional paid-in capital in the condensed consolidated statement of stockholders’ equity.

On August 13, 2021, thirty days following the achievement of a defined clinical milestone, the remaining 3,474,902 milestone warrants dated December 24, 2019 expired and therefore such milestone warrants have been terminated and are no longer outstanding or exercisable.

Termination of Wainwright Common Stock Sales Agreement

On April 28, 2017, the Company entered into a Common Stock Sales Agreement with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent, which was amended by Amendment No. 1 to the Common Stock Sales Agreement on June 29, 2018 (the “Wainwright Sales Agreement”), pursuant to which the Company may offer and sell, from time to time, through Wainwright, shares of Common Stock having an aggregate offering price of not more than $60 million, in addition to the $2.3 million in shares sold prior to the amendment.

On July 2, 2021, the Company delivered written notice to Wainwright that it was terminating the Wainwright Sales Agreement effective July 12, 2021.

Evercore Common Stock Sales Agreement

On July 6, 2021, the Company entered into a Common Stock Sales Agreement with Evercore Group L.L.C., (“Evercore”), as sales agent (the “Evercore Sales Agreement”), pursuant to which the Company may offer and sell, from time to time, through Evercore, shares of Common Stock (the “Shares”), having an aggregate offering price of not more than $60 million. The Evercore Sales Agreement was effective on July 16, 2021, the date the Company’s shelf registration agreement on Form S-3, as filed with the SEC on July 6, 2021 ("New Registration Statement"), was declared effective by the SEC. The Shares will be offered and sold pursuant to the New Registration Statement. Subject to the terms and conditions of the Evercore Sales Agreement, Evercore will use commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company has provided Evercore with customary indemnification rights, and Evercore will be entitled to a commission at a fixed commission rate equal to 3% of the gross proceeds per Share sold. Sales of the Shares, if any, under the Evercore Sales Agreement may be made in transactions that are deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended. The Company has no obligation to sell any of the Shares and may at any time suspend sales under the Evercore Sales Agreement or terminate the Evercore Sales Agreement.

During the three months ended March 31, 2022 and 2021, the Company did not sell any shares common stock under either the Wainwright Sales Agreement or the Evercore Sales Agreement.

Common Stock Reserved for Issuance

The Company’s shares of common stock reserved for issuance as of the periods indicated were as follows:

 

 

March 31, 2022

 

 

December 31, 2021

 

April 2017 Warrants

 

 

24,725

 

 

 

24,725

 

June 2017 Warrants

 

 

41,736

 

 

 

41,736

 

December 2018 Warrants

 

 

11,332

 

 

 

11,332

 

2017 Pre-funded Warrants

 

 

775,000

 

 

 

775,000

 

Pre-funded PIPE Warrants

 

 

5,780,537

 

 

 

5,780,537

 

2021 Pre-funded Warrants

 

 

32,175,172

 

 

 

32,175,172

 

Stock options outstanding

 

 

6,199,059

 

 

 

6,218,841

 

Issued and nonvested RSUs

 

 

1,268,687

 

 

 

1,272,375

 

Total shares reserved

 

 

46,276,248

 

 

 

46,299,718

 

 

Warrants

The following table summarizes the outstanding warrants for the Company’s common stock as of March 31, 2022:

Expiration Date

 

Shares Underlying
Outstanding Warrants

 

 

Exercise Price

 

October 2024

 

 

775,000

 

 

$

0.01

 

April 2027

 

 

24,725

 

 

$

2.87

 

June 2027

 

 

41,736

 

 

$

2.87

 

December 2028

 

 

11,332

 

 

$

2.87

 

None

 

 

37,955,709

 

 

$

0.001

 

 

 

 

38,808,502

 

 

 

 

 

 

Accumulated Other Comprehensive Income (Loss) Information

The components of accumulated other comprehensive income (loss) as of the dates indicated and the change during the period were (in thousands):

 

 

Foreign Exchange Translation Adjustment

 

 

Unrealized Gain (Loss) on ST Investments

 

 

Total Accumulated Other Comprehensive Income (Loss)

 

Balance, December 31, 2020

 

$

941

 

 

$

1

 

 

$

942

 

Change

 

 

(887

)

 

 

(50

)

 

 

(937

)

Balance, December 31, 2021

 

 

54

 

 

$

(49

)

 

 

5

 

Change

 

 

(208

)

 

 

(88

)

 

 

(296

)

Balance, March 31, 2022

 

$

(154

)

 

$

(137

)

 

$

(291

)